Pharmaceutical - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

26 to 50 of 320 results

Positive Ph III data for AstraZeneca’s lesinurad in gout patients

17-11-2014

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results of two pivotal Phase III…

allopurinolAnti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Almirall profits leap in first nine months of 2014

Almirall profits leap in first nine months of 2014

10-11-2014

Almirall, Spain’s largest drugmaker, has reported strong financial results for the first-three quarters…

AlmirallAstraZenecaEkliraFinancialPharmaceuticalSpain

AstraZeneca’s olaparib shows success in tumor response rate for patients with BRCA-related cancers

07-11-2014

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26%…

AstraZenecaLynparzaolaparibOncologyPharmaceuticalResearch

AstraZeneca raises forecast on strong third quarter

AstraZeneca raises forecast on strong third quarter

06-11-2014

AstraZeneca, the Anglo-Swedish pharma major which defended itself against a £73.82 billion ($118 billion)…

AstraZenecaFinancialPharmaceutical

UPDATE: AstraZeneca divests Myalept for $325 million

06-11-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a definitive agreement…

Aegerion PharmaceuticalsAstraZenecaMergers & AcquisitionsMyaleptPharmaceuticalRare diseases

Isis Pharmaceuticals receives first $7.5 million milestone payment from AstraZeneca for ISIS-STAT3

Isis Pharmaceuticals receives first $7.5 million milestone payment from AstraZeneca for ISIS-STAT3

05-11-2014

US pharma company Isis Pharmaceuticals has earned the first of two milestone payments from Anglo-Swedish…

AstraZenecaIsis PharmaceuticalsISIS-STAT3RxOncologyPharmaceuticalResearchUSA

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

Almirall transfers rights to respiratory business to AstraZeneca

Almirall transfers rights to respiratory business to AstraZeneca

03-11-2014

Spanish pharma company Almirall has transferred the rights to its respiratory franchise to Anglo-Swedish…

AlmirallAstraZenecaEkliraPharmaceuticalResearchRespiratory and PulmonarySpain

US FDA approves AstraZeneca’s Xigduo XR

US FDA approves AstraZeneca’s Xigduo XR

30-10-2014

The US Food and Drug Administration has approved Anglo-Swedish pharma major AstraZeneca’s once-daily…

AstraZenecaDiabetesPharmaceuticalRegulationUSAXigduo XR

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

30-10-2014

Anglo-Swedish drug major AstraZeneca has entered into a strategic collaboration with the University of…

AstraZenecaHealth Medical PharmaPharmaceuticalResearchUK

AstraZeneca’s Lynparza backed for approval by EMA committee

AstraZeneca’s Lynparza backed for approval by EMA committee

24-10-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

AstraZenecaEuropeLynparzaolaparibOncologyPharmaceuticalRegulation

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

16-10-2014

Anglo-Swedish drug major AstraZeneca, together with its global biologics R&D arm MedImmune, has entered…

AstraZenecaNeurologicalPharmaceuticalResearchUK

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Roche could lose its dominant market share in breast cancer, says IMS report

Roche could lose its dominant market share in breast cancer, says IMS report

03-10-2014

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs,…

AstraZenecaGlobalHerceptinMarkets & MarketingNovartisOncologyPharmaceuticalRochetamoxifen

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

01-10-2014

The annual congress of the European Society for Medical Oncology (ESMO) came to a close in Madrid, Spain,…

AstraZenecaAZD9291IressaOncologyPharmaceuticalResearchUK

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

26 to 50 of 320 results

COMPANY SPOTLIGHT

Menarini

Back to top